Granted Patent
B2
US 12,491,183 · App. 18/416,302 · Granted Dec 9, 2025
Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
Assignee:
ADS Therapeutics LLC
A61K31/496A61K9/0048A61K9/0051A61K9/08A61K9/107A61K31/365A61K31/404A61K31/407A61K31/416A61K31/4412A61K31/4439A61K31/444A61K31/4709A61K31/506A61K31/513A61K31/517A61K31/519A61K31/52A61K31/675A61K45/06A61K47/02A61K47/10A61K47/183A61K47/186A61K47/26A61K47/36A61K47/40A61P27/02A61P27/06
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Compositions and methods of using nintedanib for treating indications with abnormal neovascularization in the front part of the eye are disclosed.
Claims (14)
1 . A method of treating an ocular indication involving abnormal neovascularization in a front part of an eye, the method comprising topically administering to an eye of a subject an effective amount of an inhibitor of vascular endothelial growth factor receptor 1-3 (VEGFR 1-3), platelet-derived growth factor receptor α and β (PDGFR α and β), and fibroblast growth factor receptor 1-4 (FGFR 1-4);
wherein the indication involving abnormal neovascularization in a front part of an eye is graft versus host disease; atopic conjunctivitis; ocular rosacea; ocular pemphigoid; Lyell's syndrome; neovascularization induced by viral, bacterial, fungal, or parasitic infection; contact lens induced neovascularization; ulceration; alkali burns; stem cell deficiency; pinguecula; neovascular glaucoma; Sjogren's syndrome; Meibomian gland dysfunction; or tumor in the eye.
2 . The method of claim 1 , wherein the indication involving abnormal neovascularization in a front part of an eye is stem cell deficiency.
3 . A method of treating an ocular indication involving abnormal neovascularization, the method comprising topically administering to an eye of a subject an effective amount of an inhibitor of vascular endothelial growth factor receptor 1-3 (VEGFR 1-3), platelet-derived growth factor receptor α and β (PDGFR α and β), and fibroblast growth factor receptor 1-4 (FGFR 1-4); wherein the indication involving abnormal neovascularization is corneal graft rejection after corneal transplant.
4 . The method of claim 3 , wherein the inhibitor is administered in an amount effective to prevent graft rejection by inhibiting abnormal neovascularization and inflammation in the eye of the subject.
5 . The method of claim 1 , wherein the inhibitor is in the form of a topical ocular formulation, wherein the topical ocular formulation is a solution, suspension, cream, ointment, gel, gel-forming liquid, suspension containing liposomes or micelles, spray formulation, or emulsion.
6 . The method of claim 1 , wherein the inhibitor is in the form of a topical eye drop.
7 . The method of claim 1 , further comprising administering to the eye of the subject an effective amount of an antimetabolite.
8 . The method of claim 7 , wherein the antimetabolite is selected from the group consisting of mycophenolate mofetil, methotrexate, mitomycin C, 5-fluorouracil, azathioprine, and thiotepa.
9 . The method of claim 1 , wherein the inhibitor is axitinib or a pharmaceutically acceptable salt thereof.
10 . The method of claim 2 , wherein the inhibitor is axitinib or a pharmaceutically acceptable salt thereof.
11 . The method of claim 1 , wherein the indication involving abnormal neovascularization in a front part of an eye is atopic conjunctivitis; ocular rosacea; ocular pemphigoid; Lyell's syndrome; neovascularization induced by viral, bacterial, fungal, or parasitic infection; ulceration; stem cell deficiency; pinguecula; neovascular glaucoma; Sjogren's syndrome; Meibomian gland dysfunction; or tumor in the eye.
12 . The method of claim 11 , wherein the inhibitor is axitinib, cediranib, linifanib, motesanib, nintedanib, pazopanib, regorafenib, sunitinib, or tivozanib, or a pharmaceutically acceptable salt thereof.
13 . The method of claim 11 , wherein the inhibitor is nintedanib or a pharmaceutically acceptable salt thereof.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 3, 2024
From: NI, JINSONG; YANG, RONG
To: CLOUDBREAK THERAPEUTICS, LLC
Reel/Frame 066988/0426 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 3, 2024
From: CLOUDBREAK THERAPEUTICS, LLC
To: ADS THERAPEUTICS LLC
Reel/Frame 066988/0525 →
Continuity (5)
Continuation
16306152
Provisional Application
62344878
· Jun 2, 2016
Provisional Application
62344870
· Jun 2, 2016
References Cited (245)
US 8747852B1
· Pham
· 2014
[cited by applicant]
US 9980901B2
· Ni
· 2018
[cited by applicant]
US 9987223B2
· Ni
· 2018
[cited by applicant]
US 20060052286A1
· Garen et al.
· 2006
[cited by applicant]
US 20080003219A1
· Peyman
· 2008
[cited by applicant]
US 20100098772A1
· Robinson et al.
· 2010
[cited by applicant]
US 20100185564A1
· King et al.
· 2010
[cited by applicant]
US 20130012531A1
· King
· 2013
[cited by applicant]
US 20130316006A1
· Popov et al.
· 2013
[cited by applicant]
US 20140057908A1
· Smith
· 2014
[cited by examiner]
US 20140186336A1
· Pham
· 2014
[cited by applicant]
US 20140235678A1
· Böttger et al.
· 2014
[cited by applicant]
US 20150037422A1
· Kaplan et al.
· 2015
[cited by applicant]
US 20150141448A1
· Bottger et al.
· 2015
[cited by applicant]
US 20150164790A1
· Bottger et al.
· 2015
[cited by applicant]
US 20150258120A1
· Zarnitsyn et al.
· 2015
[cited by applicant]
US 20160038760A1
· Hamrah et al.
· 2016
[cited by applicant]
US 20220331310A1
· Ni
· 2022
[cited by applicant]
US 20240148643A1
· Robinson et al.
· 2024
[cited by applicant]
US 20250262148A1
· Ni
· 2025
[cited by applicant]
CA 2989121
· 2016
[cited by applicant]
CN 1247469
· 2000
[cited by applicant]
CN 100455568
· 2009
[cited by applicant]
CN 102018686
· 2011
[cited by applicant]
CN 103212075
· 2013
[cited by applicant]
CN 103889399
· 2014
[cited by applicant]
CN 103998431
· 2014
[cited by applicant]
CN 104379128
· 2015
[cited by applicant]
CN 104379129
· 2015
[cited by applicant]
CN 104379133
· 2015
[cited by applicant]
CN 104448300
· 2015
[cited by applicant]
CN 103732623
· 2017
[cited by applicant]
CN 107708664
· 2018
[cited by applicant]
CN 110072849
· 2019
[cited by applicant]
CN 108135737
· 2021
[cited by applicant]
EP 3463315
· 2023
[cited by applicant]
JP 2013518049A
· 2013
[cited by applicant]
JP 2014518064
· 2014
[cited by applicant]
JP 2015007117A
· 2015
[cited by applicant]
JP 2016501849
· 2016
[cited by applicant]
JP 2016040313
· 2016
[cited by applicant]
JP 2018521120A
· 2018
[cited by applicant]
JP 2018524327A
· 2018
[cited by applicant]
KR 20150083117
· 2015
[cited by applicant]
RU 2351298
· 2009
[cited by applicant]
WO WO2001002369
· 2001
[cited by applicant]
WO WO2007012974
· 2007
[cited by applicant]
WO WO2007038453
· 2007
[cited by applicant]
WO WO2008122858
· 2008
[cited by applicant]
WO WO2009147212
· 2009
[cited by applicant]
WO WO2009147220
· 2009
[cited by applicant]
WO WO2010111449A1
· 2010
[cited by applicant]
WO WO2012167143
· 2012
[cited by applicant]
WO WO2013105895
· 2013
[cited by applicant]
WO WO2013188268
· 2013
[cited by applicant]
WO WO2013188283
· 2013
[cited by applicant]
WO WO2013188268A1
· 2013
[cited by examiner]
WO WO2014074823
· 2014
[cited by applicant]
WO WO2014078655
· 2014
[cited by applicant]
WO WO2014074823A1
· 2014
[cited by examiner]
WO WO2014165308A2
· 2014
[cited by applicant]
WO WO2014204791
· 2014
[cited by applicant]
WO WO2015108787
· 2015
[cited by applicant]
WO WO2016029191
· 2016
[cited by applicant]
WO WO2016209555
· 2016
[cited by applicant]
WO WO2017120600A1
· 2017
[cited by examiner]
WO WO2017210130
· 2017
[cited by applicant]
WO WO2018022437
· 2018
[cited by applicant]
WO WO2018054077
· 2018
[cited by applicant]
WO WO2018064354
· 2018
[cited by applicant]
WO WO2019226864
· 2019
[cited by applicant]
WO WO2020103958
· 2020
[cited by applicant]
WO WO2021168218
· 2021
[cited by applicant]
WO WO2023103835
· 2023
[cited by applicant]
Hojjat-Farsangi, Int. J. Mol. Sci. 2014, 15, 13768-13801; doi: 10.3390/1jms150813768 (Year: 2014).
[cited by examiner]
Alcon Protocol C-09-023, A Dose-Escalation Study of AL-39324 Suspension versus Lucentis® for the Treatment of Exudative Age-Related Macular Degeneration, 2011, pp. 6-7 (Year: 2011).
[cited by examiner]
“Concise Description of Relevance of International Patent Application Publication No. WO 2007 /038453 to Pending Claims of U.S. Appl. No. 15/474,620,” Third-Party Submission Under 37 CRF 1.290 in U.S. Appl. No. 15/474,6…
[cited by applicant]
“Concise Description of Relevance of International Patent Application Publication No. WO 2013/188283 to Pending Claims of U.S. Appl. No. 15/474,620,” Third-Party Submission Under 37 CRF 1.290 in U.S. Appl. No. 15/474,62…
[cited by applicant]
“Concise Description of Relevance of International Patent Application Publication No. WO 2016/209555 to Pending Claims of U.S. Appl. No. 15/474,620,” Third-Party Submission Under 37 CRF 1.290 in U.S. Appl. No. 15/474,62…
[cited by applicant]
“Concise Description of Relevance of Roskoski, Biochemical and Biophysical Research Communications 356 (2007) 323-328 to Pending Claims of U.S. Appl. No. 15/474,620,” Third-Party Submission Under 37 CRF 1.290 in U.S. Ap…
[cited by applicant]
“Concise Description of Relevance of Roth et al. J. Med. Chem. (2015) 58, 1053-1063 to Pending Claims of U.S. Appl. No. 15/474,620,” Third-Party Submission Under 37 CRF 1.290 in U.S. Appl. No. 15/474,620, dated Oct. 20,…
[cited by applicant]
“Third Party Pre-Issuance Submission Pursuant to 35 U.S.C. § 122(e) and 37 C.F.R. §1.290 for U.S. Appl. No. 15/474,620,” Third-Party Submission Under 37 CRF 1.290 in U.S. Appl. No. 15/474,620, dated Oct. 20, 2017, 3 pag…
[cited by applicant]
“Third-Party Submission Under 37 CFR 1.290 Concise Description of Relevance, for U.S. Appl. No. 15/474,620,” Third-Party Submission Under 37 CRF 1.290 in U.S. Appl. No. 15/474,620, dated Oct. 20, 2017, 4 pages.
[cited by applicant]
[No Author Listed], “Clinical Pharmacology and Biopharmaceutics Review(s),” Center for Drug Evaluation and Research, submitted by Boehringer Ingelheim, Inc. on May 2, 2014, 140 pages (Exhibit No. 1026).
[cited by applicant]
[No Author Listed], “EPAR Summary for the Public: Vargatef (nintedanib),” European Medicines Agency, © 2015, 3 pages (Exhibit No. 1013).
[cited by applicant]
[No Author Listed], “OFEV (nintedanib) FDA Label,” Boehringer Ingelheim Pharmaceuticals, Inc., © 2014, 18 pages (Exhibit No. 1012).
[cited by applicant]
[No Author Listed], “Standard Affidavit,” Internet Archive Standard Affidavit, 2020, 2 pages, retrieved from URL: https://archive.org/legal/affidavit/php, retrieved on Jul. 31, 2020 (Exhibit No. 1029).
[cited by applicant]
[No Author Listed], “Table of Contents,” IOVS, 2013, 54(1):1-24, retrieved from URL: https://web.archive.org/web/20131008205602/http:/www.iovs.org/content/54/1.toc, retrieved on Jul. 30, 2020 (Exhibit No. 1028).
[cited by applicant]
Affidavit of Elizabeth Rosenberg, dated Aug. 5, 2020, 22 pages (Exhibit No. 1030).
[cited by applicant]
[cited by applicant]
[cited by applicant]
[cited by applicant]
[cited by applicant]
[cited by applicant]
[cited by applicant]
Al-Torbak, “Photodynamic Therapy with Verteporfin for Corneal Neovascularization,” Middle East Afr. J. Opthalmol., Apr.-Jun. 2012, 19(2):185-189.
[cited by applicant]
Amoozgar et al., “A role for antimetabolites in glaucoma tube surgery: current evidence and future directions,” Curr Opin Ophthalmol., 2016, 27(2):164-9.
[cited by applicant]
Amparo et al., “Safety and Efficacy of the Multitargeted Receptor Kinase Inhibitor Pazopanib in the Treatment of Corneal Neovascularization,” Investigative Ophthalmology & Visual Science, Jan. 2013, 54(1):537-544.
[cited by applicant]
Avastin® (bevacizumab) “Highlights of Prescribing Information,” FDA label, Sep. 2011, 25 pages.
[cited by applicant]
Aversa et al., “Linifanib: current status and future potential in cancer therapy,” Expert Review of Anticancer Therapy, Jun. 3, 2015, 15(6):677-87.
[cited by applicant]
Bayyoud et al., “Cytotoxic Properties of Sunitinib and Sorafenib on Human Corneal Epithelial Cells,” Current Eye Research, Feb. 2014, 39(2):149-154.
[cited by applicant]
Belghmaidi et al., “Management of corneal neovascularization prior to corneal transplantation: Report of 112 cases,” J. Fr. Opthalmol, Jun. 2016, 39(6):515-520 (with English Summary).
[cited by applicant]
Bhartiya et al., “The Need to maintain Intraocular Pressure over 24 Hours”, Journal of Current Glaucoma Practice, Sep. 2012, 6(3):120-123.
[cited by applicant]
Bhatti et al., “Efficacy of Topical Bevacizumab in High-Risk Corneal Transplant Survival,” Pak J Med Sci., Apr. 2013, 29(2):519-22.
[cited by applicant]
Bock et al., “Bevacizumab as a Potent Inhibitor of Inflammatory Corneal Angiogenesis and Lymphangiogenesis,” Invest Ophthalmol Vis Sci., Jun. 2007, 48(6):2545-52.
[cited by applicant]
Brandão et al., “Update on Minimally Invasive Glaucoma Surgery (MIGS) and New Implants”, Journal of Ophthalmology, Nov. 27, 2013, 12 pages.
[cited by applicant]
Campos-Mollo et al., “New Corneal Neovascularization Model in Rabbits for Angiogenesis Research,” Ophthalmic Res., Sep. 2010, 45(3):135-141.
[cited by applicant]
CAS Registry record for Nintedanib, retrieved from STN on Aug. 12, 2020, 1 page.
[cited by applicant]
Chang et al., “Corneal Neovascularization: An Anti-VEGF Therapy Review,” Survey of Opthalmol., Sep.-Oct. 2012, 57(5): 415-429.
[cited by applicant]
Chaudhary et al., “XEN Gel Implant: a new surgical approach in glaucoma,” Expert Review of Medical Devices, Jan. 2, 2018, 15(1):47-59.
[cited by applicant]
Chen et al., “Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling,” Oncotarget, Jun. 6, 2015, 6(17):14940.
[cited by applicant]
Chinese Office Action in Chinese Appln. No. 201680042858, dated Oct. 21, 2019, 12 pages (with English translation).
[cited by applicant]
Cholkar et al., “Novel Strategies for Anterior Segment Ocular Drug Delivery,” Journal of Ocular Pharmacology and Therapeutics, Mar. 2013, 29(2):106-123.
[cited by applicant]
Cox et al., “Doxycycline's Effect on Ocular Angiogenesis: an In Vivo Analysis,” Ophthalmology, Sep. 2010; 117(9):1782-91.
[cited by applicant]
Cursiefen et al., “Corneal Lymphangiogenesis: Evidence, Mechanisms, and Implications for Corneal Transplant Immunology,” Cornea, Apr. 2003, 22(3):273-81.
[cited by applicant]
Cursiefen et al., “Inhibition Of Hemangiogenesis and Lymphangiogenesis After Normal-Risk Corneal Transplantation by Neutralizing VEGF Promotes Graft Survival,” Investigative Ophthalmology & Visual Science, Aug. 2004, 45…
[cited by applicant]
Cursiefen et al., “VEGF—A Stimulates Lymphangiogenesis and Hemangiogenesis in Inflammatory Neovascularization via Macrophage Recruitment,” J Clin Invest., Apr. 2004, 113(7):1040-50.
[cited by applicant]
Daniels et al., “Imatinib Treatment for Idiopathic Pulmonary Fibrosis Randomized Placebo-controlled Trial Results”, J Respir Crit Care Med, Mar. 15, 2010, 181:604-610.
[cited by applicant]
Davis et al., “Comprehensive analysis of kinase inhibitor selectivity,” Nature Biotechnology, 2011, 29(11):1046-1051 (Exhibit No. 1016).
[cited by applicant]
Detry et al., “Sunitinib Inhibits Inflammatory Corneal Lymphangiogenesis,” Investigative Ophthalmology & Visual Science, May 2013, 54(5):3082-93.
[cited by applicant]
Elhayek et al., “Sustained Release of Bevacizumab From Hydrogel Depots for Intravitreal Injections,” Investigative Ophthalmology & Visual Science, Apr. 2014, 2 pages.
[cited by applicant]
Extended European Search Report in Application No. 16808064.6, dated Jan. 3, 2019, 8 pages.
[cited by applicant]
Fala et al., “Ofev (Nintedanib): First Tyrosine Kinase Inhibitor Approved for the Treatment of Patients with Idiopathic Pulmonary Fibrosis,” Am Health Drug Benefits, Special Feature, Mar. 2015, 8:101-104.
[cited by applicant]
Fossarello et al., “Photodynamic Therapy of Corneal Neovascularization with Verteporfin,” Cornea, Jul. 1, 2003, 22(5):485-488.
[cited by applicant]
Fossarello et al., “Photodynamic Therapy of Pterygium With Verteporfin: A Preliminary Report,” Cornea, May 2004, 23(4): 330-338.
[cited by applicant]
Fotouhi et al., “Prevalance and risk factors of pterygium and pinguecula: the Tehran Eye Study,” Nature, May 2009, 1125-1129.
[cited by applicant]
Gedde et al., “Treatment Outcomes in the Tube Versus Trabeculectomy (TVT) Study After Five Years of Follow-up”, Am J Ophthalmol., May 2012, 153(5):789-803.
[cited by applicant]
Gougis et al., “Clinical pharmacology of anti-angiogenic drugs in oncology,” Critical Reviews in Oncology / Hematology, Nov. 2017, 119:75-93 (Exhibit No. 1024).
[cited by applicant]
Gover-Proaktor et al., “Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells,” Leukemia & lymphoma, Jan. 2, 2019, 60…
[cited by applicant]
Hall et al., “Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC),” Transl Lung Cancer Res., Oct. 2015, 4(5):515-23.
[cited by applicant]
Harooni et al., “Letter to the Editor: Bevacizumab for Graft Rejection,” Opthamology, Oct. 2007, 114(10):P1950, 2 pages.
[cited by applicant]
Hilberg et al, “BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy,” Cancer Res., Jun. 15, 2008, 68(12):4774-4782.
[cited by applicant]
Hojjat-Farsangi, “Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies,” Int. J. Mol. Sci., Aug. 8, 2014, 15:13768-13801.
[cited by applicant]
Hos et al., “Inflammatory Corneal (Lymph)angiogenesis Is Blocked by VEGFR-Tyrosine Kinase Inhibitor ZK 261991, Resulting in Improved Graft Survival after Corneal Transplantation,” Investigative Opthalmology & Visual Sci…
[cited by applicant]
Hostettler et al., “Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis,” Respiratory research, Dec. 2014, 15:157.
[cited by applicant]
Hueber et al., “Photodynamic therapy for wound-healing modulation in pterygium surgery. A clinical pilot study,” Graefe's Arch Clin Exp Opthalmol, Apr. 2005, 243:942-946.
[cited by applicant]
Huu et al, “Light-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor in the posterior segment of the eye” Journal of Controlled Release, Feb. 28, 2015, 200:71-77.
[cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US16/35726, mailed Dec. 12, 2017, 9 pages.
[cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2020/050150, mailed Mar. 24, 2022, 7 pages.
[cited by applicant]
International Search Report and Written Opinion in Application No. PCT/US17/34792, dated Oct. 25, 2017, 14 pages.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US16/35726, mailed Sep. 1, 2016, 13 pages.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US17/34795, mailed Aug. 23, 2017, 10 pages.
[cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2020/050150, dated Mar. 26, 2021, 8 pages.
[cited by applicant]
Inventor Declaration filed during the Prosecution of US Patent Application Publication No. 20130012531 to King et al., dated Sep. 2012, 3 pages (Exhibit No. 1020).
[cited by applicant]
Jaros et al., “Diagnostic and Surgical Techniques,” Survey of Ophthalmology, Jul. 1988, 33(1), 9 pages.
[cited by applicant]
Jo et al., “Inhibition of Platelet-Derived Growth Factor B Signaling Enhances the Efficacy of Anti-Vascular Endothelial Growth Factor Therapy in Multiple Models of Ocular Neovascularization,” Am J Pathol., Jun. 2006, 16…
[cited by applicant]
Jovanovic et al., “The Effect of Topical Doxycycline on Corneal Neovascularization,” Current Eye Research, Feb. 1, 2014, 39(2):142-148.
[cited by applicant]
Kaplowitz et al., “Techniques and outcomes of minimally invasive trabecular ablation and bypass surgery,” British Journal of Ophthalmology, May 2014, 98(5):579-85.
[cited by applicant]
Kareem et al, “The use of antimetabolites as adjunctive therapy in the surgical treatment of pterygium” Clinical Ophthalmology, Nov. 7, 2012, 6 pages.
[cited by applicant]
Katoh et al., “FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis,” International journal of molecular medicine, Jul. 2016, 38(1):3-15.
[cited by applicant]
Kaufman et al., “Options and adjuvants in surgery for pterygium: a report by the American Academy of Ophthalmology,” Ophthalmology, Jan. 2013, 120(1):201-208.
[cited by applicant]
Kay et al., “Imatinib mesylate treatment of nephrogenic systemic fibrosis,” Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, Aug. 2008, 58(8):2543-8.
[cited by applicant]
Kinoshita et al., “Please Tell Me About Pterygium, Pseudopterygium, Ocular Cicatricial Pemphigoid,” New Opthamology, J. of the Eye, Dec. 30, 2014, 31:8-9 (with English translation).
[cited by applicant]
Kitagawa et al., “Activity-based kinase profiling of approved tyrosine kinase inhibitors,” Genes to Cells, 2013, 18:110-122.
[cited by applicant]
Ko et al., “Inhibition of Corneal Neovascularization by Subconjunctival and Topical Bevacizumab and Sunitinib in a Rabbit Model,” Cornea, May 2013, 32(5):689-695.
[cited by applicant]
Kria, “Growth factors in cultured pterygium fibroblasts: immunohistochemical and ELISA analysis, ” Graefe's Arch for Clin. Exp. Ophthalmol., Aug. 1998, 236:702-708.
[cited by applicant]
Kria, “Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-beta and tumor necrosis factor-a in the pterygium,” Acta Histochem, Apr. 1996, 98:195…
[cited by applicant]
Kumar et al., “Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors,” British Journal of Cancer, Oct. 2009, 101:1717-1723.
[cited by applicant]
Lee et al., “Effect of porcine chondrocyte-derived extracellular matrix on the pterygium in mouse model,” Graefes Arch Clin Exp Ophthalmol., Apr. 2014, 252(4):609-618.
[cited by applicant]
Lee et al., “Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis,” ASTR, Jul. 2015, 8 pages.
[cited by applicant]
Letter of the Proprietor to the EPO in European Appln. No. 17807296.3, mailed on Jul. 20, 2020, 9 pages.
[cited by applicant]
Li et al., “Controlled Release of Bevacizumab Through Nanospheres for Extended Treatment of Age-Related Macular Degeneration,” Open Ophthalmol J., Jun. 11, 2012, 6:54-8.
[cited by applicant]
Lin et al., “Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib,” Drug Design, Development and Therapy, Apr. 2017, 11:1147-1158.
[cited by applicant]
Livezeanu et al., “Angiogenesis in the pathogenesis of pterygium,” Rom. J. Morph. Embryol, Jan. 2011, pp. 837-844.
[cited by applicant]
Lucentis® Label, Clinical Trial Date Dec. 2011, 9 pages.
[cited by applicant]
Maddula et al, “Horizons in Therapy for Corneal Angiogenesis,” Ophthalmology, Mar. 2011, 118(3):591-599.
[cited by applicant]
Manallack et al., “The significance of acid/base properties in drug discovery,” Chem. Soc. Rev., 2013, 42:485-496 (Exhibit No. 1018).
[cited by applicant]
Masoumpour et al., “Current and future techniques in wound healing modulation after glaucoma filtering surgeries,” The Open Ophthalmology Journal, 2016, 10(1):68-85.
[cited by applicant]
Memorandum from Deputy Commissioner from Patent Examination Policy to Patent Examining Corps, dated Apr. 5, 2018, 7 pages (Exhibit No. 1019).
[cited by applicant]
Mésange et al., “Intrinsic Bevacizumab Resistance Is Associated With Prolonged Activation of Autocrine VEGF Signaling And Hypoxia Tolerance in Colorectal Cancer Cells and Can Be Overcome by Nintedanib, A Small Molecule …
[cited by applicant]
Mimura et al., “Severity and Determinants of Pinguecula in a Hospital-Based Population,” Eye & Contact Lens: Science & Clinical Practice, Jan. 2011, 37:31-35.
[cited by applicant]
Morrison et al., “Advances in ophthalmic drug delivery,” Therapeutic Delivery, Dec. 2014 5(12):1297-1315.
[cited by applicant]
nhs.uk [online], “Overview: Cornea Transplant,” Mar. 7, 2024, retrieved on Jun. 3, 2024, retrieved from URL <https://www.nhs.uk/conditions/cornea-transplant/>, 2 pages.
[cited by applicant]
Notice of Opposition in European Appln. No. 17807296.3, mailed on Mar. 19, 2024, 29 pages.
[cited by applicant]
OFEV Capsules Approval Letter, Application No. 205832Orig1s000, 8 pages, Approval date Oct. 15, 2014.
[cited by applicant]
O'Hare et al., “AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance,” Cancer Cell, Nov. 3, 2009, 16(5):401-412.
[cited by applicant]
Onder et al., “Inhibitory Effects of Regorafenib, a Multiple Tyrosine Kinase Inhibitor, on Corneal Neovascularization,” Int J Ophthalmol., Apr. 18, 2014, 7(2):220-5.
[cited by applicant]
Ornitz et al., “The Fibroblast Growth Factor signaling pathway”, WIREs Dev Biol., vol. 4, 215-266, 2015, 52 pages.
[cited by applicant]
Oxford Handbook of Ophthalmology, Oxford University Press, Jan. 2014, Chapter 26, pp. 1003-1021.
[cited by applicant]
Pandey, “Assessment of the Most Common Pterygium Symptoms and Risk Factors Leading to the Decision for its Surgical Removal—A long term study,” Semantic Scholar, Mar. 2017, 4 pages.
[cited by applicant]
PCT International Publication No. WO 2007038453, published on Apr. 5, 2007, Peyman et al., 54 pages (Exhibit No. 1010).
[cited by applicant]
PCT International Publication No. WO 2016209555, published on Dec. 29, 2016, Nguyen et al., 42 pages (Exhibit No. 1006).
[cited by applicant]
Peng, “Vascular endothelial growth factor gene polymorphism and protein expression in pathogenesis of pterygium,” Br J Ophthalmol., Apr. 2013, 98:556-561.
[cited by applicant]
Perez-Santonja et al., “Inhibition of Corneal Neovascularization by Topical Bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an Animal Model,” Am J Ophthalmol., Oct. 2010, 150(4):519-528.
[cited by applicant]
Pozarowska et al., “The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy,” Cent. Eur. J. Immunol., Jan. 2016, 41(3):311-316.
[cited by applicant]
Prosecution History of U.S. Pat. No. 10,149,820, filed on May 29, 2018, 132 pages (Exhibit No. 1002).
[cited by applicant]
Prosecution History of U.S. Pat. No. 10,154,994, filed on Sep. 11, 2017, 709 pages (Exhibit No. 1015).
[cited by applicant]
Prosecution History of U.S. Pat. No. 9,987,223, filed on Apr. 11, 2017, 562 pages (Exhibit No. 1025).
[cited by applicant]
Pterygium: Techniques and Technologies for Surgical Success, 1st edition, CRC Press (ed)., Chapter 1, Jul. 15, 2011, 26 pages.
[cited by applicant]
Qazi et al., “ Corneal allograft rejection: immunopathogenesis to therapeutics,” J. Clin Cell. Immunol., Nov. 20, 2013, 21 pages.
[cited by applicant]
Rauck et al., “Biocompatible Reverse Thermal Gel Sustains the Release of Intravitreal Bevacizumab In Vivo,” Investigative Ophthalmology & Visual Science, Jan. 2014, 55(1):469-476.
[cited by applicant]
Response to Office Action in U.S. Appl. No. 16/210,896, filed Apr. 10, 2020, 20 pages (Exhibit No. 1023).
[cited by applicant]
Rivera et al., “BIBF1120 (Vargatef) Inhibits Preretinal Neovascularization and Enhances Normal Vascularization in a Model of Vasoproliferative Retinopathy,” Investigative Ophthalmology & Visual Science, Dec. 2015, 56(13…
[cited by applicant]
Roskoski Jr., “Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor,” Biochem. Biophys. Res. Comm., May 4, 2007, 356:323-328.
[cited by applicant]
Roskoski, “Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes,” Pharmacological Research, Jan. 2016, 103:26-48 (Exhibit No. 1017).
[cited by applicant]
Roth et al., “Nintedanib: From Discovery to the Clinic,” J. Med. Chem., Dec. 4, 2014, 58(3):1053-1063.
[cited by applicant]
Rúa et al., “Oral Doxycycline Reduces Pterygium Lesions; Results from a Double Blind, Randomized, Placebo Controlled Clinical Trial,” Plos One, Dec. 2012, 7(12):e52696, 7 pages.
[cited by applicant]
Schiffman et al., “Reliability and validity of the Ocular Surface Disease Index,” Arch Ophthalmol., May 2000, 118(5):615-621.
[cited by applicant]
Schlunck et al., “Conjunctival fibrosis following filtering glaucoma surgery,” Exp Eye Res., Jan. 2016, 142:76-82.
[cited by applicant]
Sonoda et al., “ACAID induced by allogeneic corneal tissue promotes subsequent survival of orthotopic corneal grafts,” Invest Ophthalmol Vis Sci., Mar. 2000, 41(3):790-8.
[cited by applicant]
Sonoda et al., “Characterization of cell-mediated immune responses elicited by orthotopic corneal allografts in mice,” Invest Ophthalmol Vis Sci., Feb. 1995, 36(2):427-34.
[cited by applicant]
Supplementary European Search Report in EP Appln. No. 17807295, dated Jan. 29, 2020, 7 pages.
[cited by applicant]
Third Party Submission Under 37 CFR 1.290 for U.S. Appl. No. 15/474,620, dated Oct. 20, 2017, 3 pages.
[cited by applicant]
U.S. Appl. No. 62/183,180, filed Jun. 22, 2015, 14 pages.
[cited by applicant]
US Patent Application Publication No. 2008/0003219, published on Jan. 3, 2008, Peyman, 11 pages (Exhibit No. 1021).
[cited by applicant]
US Patent Application Publication No. 2013/0012531, published on Jan. 10, 2013, King et al., 13 pages (Exhibit No. 1008).
[cited by applicant]
U.S. Pat. No. 10,149,820, issued on Dec. 11, 2018, 20 pages (Exhibit No. 1001).
[cited by applicant]
U.S. Appl. No. 62/172,063, filed Jun. 6, 2015, 18 pages (Exhibit No. 1003).
[cited by applicant]
U.S. Appl. No. 62/183,180, filed Jun. 22, 2015, 24 pages (Exhibit No. 1007).
[cited by applicant]
U.S. Appl. No. 62/186,660, filed Jun. 30, 2015, 20 pages (Exhibit No. 1004).
[cited by applicant]
Van Bergen et al., “Inhibition of placental growth factor improves surgical outcome of glaucoma surgery,” J Cell Mol Med., Dec. 2013, 17(12):1632-1643.
[cited by applicant]
Vandewalle et al., “Intracameral bevacizumab as an adjunct to trabeculectomy: a 1-year prospective, randomised study,” Br J Ophthalmol., Jan. 2013, 98(1):1-6.
[cited by applicant]
Wang et al., “Clinical Observation on Pterygium Excision Combined With Autologous Conjunctiva Transplantation,” Chinese Journal of Ophthalmology and Otorhinolaryngology, Sep. 25, 2012, 4 pages, with machine translation.
[cited by applicant]
Wikipedia.com [online], “Neovascularization,” retrieved on Jun. 3, 2024 retrieved from URL <https://en.wikipedia.org/wiki/Neovascularization#:˜:text=Neovascularization%20is%20the%20natural%20formation,local%20poor%20per…
[cited by applicant]
Wollin et al., “Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis, ” Eur. Respir. J., May 2015, 45(5):1434-1445.
[cited by applicant]
Wong et al., “Matrix metalloproteinase inhibition modulates postoperative scarring after experimental glaucoma filtration surgery,” Invest Ophthalmol Vis Sci., Mar. 2003, 44(3):1097-1103.
[cited by applicant]
Xu et al., “Recent Advances in Drug Therapy of Corneal Neovascularization,” Recent Advances in Opthalmology, Oct. 31, 2015, 989-993, 11 pages (with machine translation).
[cited by applicant]
Abdelfattah et al., “Clinical correlates of common corneal neovascular diseases: a literature review,” Int J Ophthalmol, Feb. 18, 2015, 8(1):182-93.
[cited by applicant]
Giacomini et al., “Alkali burn versus suture-induced corneal neovascularization in C57BL/6 mice: An overview of two common animal models of corneal neovascularization,” 2014, 121:1-4, 3 pages (abstract only).
[cited by applicant]
Isalan, “Gene networks and liar paradoxes,” Bioessays, Oct. 2009, 31(10):1110-5.
[cited by applicant]
Magalhaes et al., “Literature review and suggested protocol for prevention and treatment of corneal graft rejection,” Eye, Mar. 2020, 34(3):442-50.
[cited by applicant]
Rand.org [online], “National Eye Institute Visual Functioning Questionnaire,” Jan. 2020, retrieved on Apr. 23, 2025, retrieved from URL <https://www.rand.org/content/dam/rand/www/external/health/surveys_tools/vfq/vfq25s…
[cited by applicant]
Vinciguerra et al., “Long-term resolution of immunological graft rejection after a dexamethasone intravitreal implant,” Cornea, Apr. 2015, 34(4):471-4.
[cited by applicant]
Boxerwachler.com [online], “What are Pterygium?,” available on or before Feb. 6, 2015, Internet Archive: Wayback Machine URL <https://web.archive.org/web/20150206211720U /https://www.boxerwachler.com/pterygium-removal>,…
[cited by applicant]